Saturday, July 13, 2024 3:39:05 PM
When it comes to how NWBO can pay for all the growth that's about to happen in the next few years, there's an expression used in multi-level marketing that I believe should apply. Incorporate the work of others.
I can believe that companies, like CRL, will pay for the rights to lease the EDEN and become the CDMO for providing the DCVax's throughout much of the world. I believe Merck will pay much, if not all the costs of running trials that prove the Keytruda has benefits when used with DCVax-L in many solid cancers. I'd not be surprised if NWBO would like to acquire Oncovir in exchange for stock, but not until the price is dramatically higher.
In terms of equity partnerships, I believe that there are BP's who'd be willing to purchase a substantial percentage of NWBO who're willing to pay the $20 or more that LP demands, but not until NWBO's stock price has reached approximately 50% of what they're willing to pay. I'm speaking of billions coming in, but not until the share price is right.
In short, I'm saying that many will pay for the right to work with NWBO, it won't require a huge investment by NWBO in things like production facilities, many trials will be supported by others, etc. Certainly they need to grow, but the growth need not be tremendous as others do the work, and NWBO is paid.
Gary
I can believe that companies, like CRL, will pay for the rights to lease the EDEN and become the CDMO for providing the DCVax's throughout much of the world. I believe Merck will pay much, if not all the costs of running trials that prove the Keytruda has benefits when used with DCVax-L in many solid cancers. I'd not be surprised if NWBO would like to acquire Oncovir in exchange for stock, but not until the price is dramatically higher.
In terms of equity partnerships, I believe that there are BP's who'd be willing to purchase a substantial percentage of NWBO who're willing to pay the $20 or more that LP demands, but not until NWBO's stock price has reached approximately 50% of what they're willing to pay. I'm speaking of billions coming in, but not until the share price is right.
In short, I'm saying that many will pay for the right to work with NWBO, it won't require a huge investment by NWBO in things like production facilities, many trials will be supported by others, etc. Certainly they need to grow, but the growth need not be tremendous as others do the work, and NWBO is paid.
Gary
Bullish
Recent NWBO News
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 04/21/2026 04:15:08 AM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 04/16/2026 09:25:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/07/2026 04:30:50 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/31/2026 09:04:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/15/2026 10:06:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2026 10:14:59 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/28/2025 09:43:27 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/25/2025 10:23:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2025 09:26:03 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/19/2025 09:15:48 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:44:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2025 04:29:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2025 08:40:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/24/2025 04:28:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/14/2025 06:22:26 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2025 09:00:38 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/01/2025 09:04:38 PM
